Everest Medicines (HKEX: 1952) discovers, develops, manufactures and commercializes medicines and vaccines with a deliberate focus on diseases that are epidemiologically disproportionate in Asia — IgA nephropathy, immune-mediated kidney diseases, and critical-care infections. Founded in 2017, the company has transitioned from a successful in-licensing model to a 'dual-engine' strategy that combines strategic global partnerships with in-house R&D.
The company is headquartered in Shanghai, China and has 812 total employees. Everest crossed from development-stage to commercial-stage company in 2024, with three approved products generating revenue in China by early 2026, and revenue grew 48% year-over-year in H1 2025 to RMB 446.1 million. Everest operates a commercial-scale manufacturing facility in Jiashan, China, and has built a robust commercialization platform anchored by blockbuster assets like Nefecon and Velsipity.
The company focuses on addressing critical unmet medical needs in the Asia-Pacific markets, particularly in Greater China, across four core therapeutic areas: autoimmune diseases, oncology, critical care, and cardiovascular, kidney, and metabolic (CKM) diseases.
Recent Leadership Developments
On October 9, 2026, Everest Medicines appointed Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences, both seasoned scientists in mRNA cancer vaccines with deep experience at Moderna and other leading biopharmaceutical companies.
Facts compiled by Executive Moves from publicly available news and press releases on 9 October 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the Everest Medicines team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
